A cost-effectiveness estimation of the Attempted Suicide Short Intervention Programme (ASSIP)
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2497877 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Max Lelie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Vrije Universiteit Brussel, Brussels, Belgium. Hauptthemen laut MEDLINE: Suicide, Attempted, Health Care Costs, Mental Health Services. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Health Technology Assessment study of ASSIP.
Abstract (Originalsprache)
OBJECTIVE: Patients who have previously attempted suicide are at a substantially increased risk of a repeated attempt. We have conducted a cost-utility analysis of the Attempted Suicide Short Intervention Programme (ASSIP) and compared it with treatment as usual in a Flemish population. METHODS: A closed-cohort Markov-model was used to simulate suicide over a time-horizon of 20 years in a cohort of prior suicide attempt patients. This model is used to estimate Incremental Cost Effectiveness Ratios (ICERs) from societal and healthcare perspectives. A separate 'tipping-point' scenario was included, where the treatment effectiveness regresses over time. RESULTS: ASSIP is shown to be a dominant strategy from the societal perspective and cost-effective from a healthcare perspective: the ICER after 10 years is € 1,133 and after 20 years € 304. In the tipping-point scenario, an regression of up to 82,7% after the intervention remains cost-effective, assuming an ICER threshold of € 44000 per QALY. CONCLUSION: Our study found that ASSIP is cost-effective in the Flemish region, saving both healthcare costs and societal expenses over time. Implementing ASSIP could provide significant economic and health benefits within 10 years, making it a valuable investment for improving mental health care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health, Vrije Universiteit Brussel, Brussels, Belgium.
- Eenheid voor Zelfmoordonderzoek, Ghent University, Ghent, Belgium.
- Faculty of Pharmaceutical Sciences, Katholieke Universiteit, Leuven, Belgium.
- Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
ORCID-Profile: Max Lelie, Riet Parmentier, Eva de Jaegere, Steven Simoens, Lieven Annemans, Koen Putman
Förderung
- Health Technology Assessment study of ASSIP
Zitieren
APA
Lelie, M., Parmentier, R., de Jaegere, E., Simoens, S., Annemans, L., & Putman, K. (2025). A cost-effectiveness estimation of the Attempted Suicide Short Intervention Programme (ASSIP). Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2497877
Vancouver
Lelie M, Parmentier R, de Jaegere E, Simoens S, Annemans L, Putman K. A cost-effectiveness estimation of the Attempted Suicide Short Intervention Programme (ASSIP). Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2497877
BibTeX
@article{Lelie2025,
author = {Lelie, Max and Parmentier, Riet and de Jaegere, Eva and Simoens, Steven and Annemans, Lieven and Putman, Koen},
title = {A cost-effectiveness estimation of the Attempted Suicide Short Intervention Programme (ASSIP)},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2497877}
}
EUVIMED